Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EBIOSS ENERGY AD. We currently have 3 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
EBIOSS ENERGY AD
EBIOSS ENERGY AD
Buy recommendation reaffirmed (Ebioss Energy)
08 Dec 16
Buy recommendation reaffirmed TARGET CHANGE CHANGE IN TARGET PRICE€ 2.12 vs 3.79 -44.0% We have updated our model following the company's new strategy with the integration of its Chinese partner. As the growth development and international focus of the company has not changed, a solution for financial support going forward with many projects simultaneously, while avoiding shareholder dilution, is a positive for both the company and investors, even if the process pushes expected revenues further ahead in time. We maintain a positive view on the group backed by our Buy recommendation as its specialised product development and know-how gives them a technological advantage over competitors, recently confirmed by the projects signed in the UK. CHANGE IN EPS2016 : € -0.09 vs 0.00 ns 2017 : € 0.00 vs 0.09 ns Due to the push forward in time of many projects under development, we have revised downwards our top-line expectations for the years to come, mainly driven by lower revenues negatively affecting our EPS estimations. Nonetheless, a lesser need of capital for future investments implies that lower financial expenses will be incurred and this partially offsets the downward pressure at the bottom-line. CHANGE IN NAV€ 1.97 vs 3.31 -40.4% Driven by the results release and the new business plan, we have revised downwards our top-line earnings expectations, which negatively impact our SOTP valuation. The negative effect has been partially offset by a decrease in expected net debt as the lighter capital model after the agreed strategic partnership provides a better financial flexibility for the company. CHANGE IN DCF€ 3.91 vs 6.99 -44.1% Following the half-year results and the new guidance provided following the agreement with its Chinese partner, we have lowered our earnings expectations and the operating cash flow for the coming years, negatively affecting our DCF valuation. However, under the new structure with less capital required for new projects in terms of debt and investment, we have also reduced capex expectations, partially offsetting the negative effect.
Target upgrade by 22.4% (Ebioss Energy)
31 May 16
TARGET CHANGE CHANGE IN EPS2016 : € 0.00 vs 0.00 +371% 2017 : € 0.09 vs 0.10 -6.63% Reported net income loss is better than expected, supported by top-line performance (revenues and earnings) above expectations, although lower on the adjusted side from lower impairment charges. Moreover, the removal of Conecta2 from the holding after the divestment of the company has no effect on 2016 estimates but slightly impacts the EPS of the group from 2017 as that was the year when the net income of the company was expected to push into positive territory. CHANGE IN NAV€ 3.31 vs 1.72 +91.9% The rollover of 2018 estimates into our model positively affects or SOTP valuation, driven by higher earnings expectations across all business units as the international footprint gains momentum with the acceleration of the commissioning of third-generation gasification units, offsetting the divestment of Conecta2 (which had little impact on the NAV due to its low earnings contribution). CHANGE IN DCF€ 6.89 vs 5.77 +19.3% After the inclusion of 2018 estimates, we have maintained our CAGR at 5% from 2018 onwards driven by positive expectations on new project developments that may arrive from the Chinese partnership agreement, supporting growth forecasts. Moreover, we have normalised capex expectations in line with the growth objectives and increased the expected invested budget as we believe a higher capex will be needed (including maintenance charges) to finance the growth forecasts. Also, the divestment of Conecta2 Energia positively affects margins (driven by the low margins provided) and has a positive effect on WCR as electricity trading requires high levels of cash to enforce output contracts in the wholesale market. Both effects combined create a positive impact and an upward revision in our DCF valuation.
Interesting partnership signature for future project development
31 May 16
Ebioss has achieved a strategic partnership agreement with the China Energy Engineering Corporation Limited International Company. After long discussions, the two-year agreement (with similar renewable terms) has been signed based on the following conditions and for projects with at least a 15% ROE: • China Energy Engineering would be responsible for turnkey projects under an Engineering Procurement & Construction contract (EPC). • China Energy Engineering would provide 75% of the required capex through Chinese or international banks, while supporting the projects with at least 50% of the required equity. Either Ebioss or third-party partners will provide the remaining stakes. • China Engineering Company would exclusively use the Ebioss technology (EGT) for all the projects involving Ebioss (a €258m project pipeline). • Following previous models, 60-70% of the required equipment would be produced in China, with no technology or property transfer as the use of the model is a patented process. Moreover, the groups are creating a combined engineering team in order to analyse and develop future projects with the required combined due diligence; Ebioss will provide the projects within Europe and China Energy Engineering would provide the ones in Asia and especially China.
Time to go over weight
24 Feb 17
We believe equity investors are taking an unnecessarily cautious stance on the construction sector. Forward looking indicators (e.g. consumer confidence, construction PMIs and housing starts) point to a stable market and recent sales LFL are particularly encouraging (e.g. Marshalls). Near term margins may suffer temporary distortions as inflationary pressures build. However, history has shown that modest input cost inflation is actually a positive for earnings growth in the sector. Therefore, as we move into 2018, margin trends are likely to surprise on the upside.
N+1 Singer - Waterman Group - Robust performance, mid-term ambitions reiterated
28 Feb 17
As trailed in the recent half year update, Waterman’s interims are in line with the prior year and in line with expectations. Both divisions recorded a robust performance despite some market uncertainties in the immediate aftermath of the EU referendum. Full year expectations are reiterated as is the medium term aspiration to increase operating margins to 6% by FY19 from 4.1% in H1’17. We see good growth opportunities in a number of areas, particularly Infrastructure & Environment, with robust conditions also in Property within retail and residential. In our view, Waterman’s shares look significantly undervalued on 4.5x FY17 EV/EBITDA compared to peers on 6.9x. We also note the attractions of a c.5% dividend yield, +33% at the interim stage.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
Encouraging trading update, boosted by FX
23 Feb 17
The group recently announced an encouraging trading update, with FY results now expected to be slightly above previous expectations, based on solid underlying trading and boosted by ongoing FX tailwinds. As such, we are modestly increasing our forecasts, with an 8.8% increase in EPS for the current year and 9.3% for 2018. This places the shares on a P/E of 16.9x in 2018. We raise our price target from 176p to 215p and, with modest upside from current levels, we maintain our Buy rating.